Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dairy Products | 3 | 2021 | 466 | 1.370 |
Why?
|
| Vitamin D | 8 | 2014 | 3138 | 0.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2022 | 10857 | 0.950 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2021 | 386 | 0.750 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 308 | 0.660 |
Why?
|
| Glycemic Index | 2 | 2019 | 385 | 0.660 |
Why?
|
| Nutrition Assessment | 1 | 2021 | 714 | 0.660 |
Why?
|
| Diabetes Mellitus | 6 | 2019 | 5348 | 0.660 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 383 | 0.590 |
Why?
|
| Leukemia | 2 | 2012 | 1496 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2012 | 1330 | 0.480 |
Why?
|
| Calcium, Dietary | 2 | 2011 | 518 | 0.430 |
Why?
|
| Overweight | 4 | 2018 | 2205 | 0.400 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 1073 | 0.400 |
Why?
|
| Body Weight | 4 | 2021 | 4680 | 0.380 |
Why?
|
| Dyslipidemias | 1 | 2016 | 843 | 0.360 |
Why?
|
| Endocrinology | 2 | 2014 | 414 | 0.360 |
Why?
|
| Blood Glucose | 6 | 2020 | 6255 | 0.340 |
Why?
|
| Hyperglycemia | 3 | 2022 | 1343 | 0.310 |
Why?
|
| Feeding Behavior | 1 | 2019 | 3141 | 0.310 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 14075 | 0.300 |
Why?
|
| Obesity | 5 | 2020 | 12031 | 0.290 |
Why?
|
| Dietary Supplements | 4 | 2014 | 3025 | 0.270 |
Why?
|
| Lipids | 1 | 2016 | 3246 | 0.270 |
Why?
|
| Diet | 2 | 2021 | 7392 | 0.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1264 | 0.260 |
Why?
|
| Vitamins | 2 | 2014 | 1466 | 0.250 |
Why?
|
| Insulin Resistance | 3 | 2014 | 3866 | 0.250 |
Why?
|
| Risk Factors | 16 | 2022 | 69553 | 0.250 |
Why?
|
| Insulin-Secreting Cells | 1 | 2011 | 976 | 0.240 |
Why?
|
| Energy Intake | 2 | 2020 | 2136 | 0.220 |
Why?
|
| Aerobiosis | 1 | 2020 | 102 | 0.200 |
Why?
|
| Fenofibrate | 1 | 2020 | 92 | 0.200 |
Why?
|
| Malaysia | 1 | 2019 | 84 | 0.190 |
Why?
|
| Hypoglycemic Agents | 2 | 2009 | 2734 | 0.190 |
Why?
|
| Insulin | 3 | 2011 | 6648 | 0.190 |
Why?
|
| Hypertension | 2 | 2016 | 8161 | 0.180 |
Why?
|
| Weight Gain | 1 | 2009 | 2193 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 3354 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7487 | 0.180 |
Why?
|
| Diet Therapy | 1 | 2019 | 159 | 0.170 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2020 | 373 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2016 | 9488 | 0.170 |
Why?
|
| Waist Circumference | 3 | 2019 | 895 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 2351 | 0.160 |
Why?
|
| Dietary Carbohydrates | 2 | 2019 | 902 | 0.160 |
Why?
|
| Nutrition Therapy | 1 | 2018 | 98 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2020 | 377 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2019 | 39292 | 0.150 |
Why?
|
| Food, Formulated | 1 | 2016 | 116 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 2019 | 755 | 0.140 |
Why?
|
| Pregnant Women | 1 | 2019 | 479 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 5044 | 0.130 |
Why?
|
| Humans | 29 | 2022 | 708843 | 0.130 |
Why?
|
| Eating | 1 | 2020 | 1443 | 0.120 |
Why?
|
| Hyperinsulinism | 1 | 2016 | 405 | 0.120 |
Why?
|
| Middle Aged | 13 | 2021 | 213752 | 0.120 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 1333 | 0.120 |
Why?
|
| Glucose Intolerance | 2 | 2020 | 575 | 0.120 |
Why?
|
| Refugees | 1 | 2019 | 454 | 0.120 |
Why?
|
| Vitamin D Deficiency | 2 | 2014 | 1356 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2017 | 363 | 0.110 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2016 | 311 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3097 | 0.110 |
Why?
|
| Female | 18 | 2021 | 375205 | 0.110 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 247 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2020 | 2042 | 0.110 |
Why?
|
| Adult | 11 | 2020 | 211041 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 796 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 846 | 0.100 |
Why?
|
| Income | 1 | 2019 | 1775 | 0.100 |
Why?
|
| Male | 16 | 2021 | 349524 | 0.100 |
Why?
|
| Incidence | 3 | 2014 | 20320 | 0.100 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2009 | 111 | 0.090 |
Why?
|
| Venoms | 1 | 2009 | 92 | 0.090 |
Why?
|
| Cholecalciferol | 1 | 2014 | 482 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2014 | 468 | 0.090 |
Why?
|
| Blood Pressure | 3 | 2020 | 8528 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2009 | 189 | 0.090 |
Why?
|
| Muscle, Skeletal | 2 | 2022 | 4969 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 952 | 0.080 |
Why?
|
| Young Adult | 4 | 2020 | 55940 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2009 | 224 | 0.080 |
Why?
|
| Fasting | 1 | 2014 | 1608 | 0.080 |
Why?
|
| Consensus | 1 | 2016 | 2713 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2022 | 6127 | 0.080 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2009 | 233 | 0.080 |
Why?
|
| Aged | 8 | 2021 | 161488 | 0.080 |
Why?
|
| Life Style | 2 | 2018 | 3636 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2011 | 11877 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 484 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 1336 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1711 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 1102 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2013 | 21194 | 0.070 |
Why?
|
| Exercise | 1 | 2020 | 5251 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2010 | 1539 | 0.060 |
Why?
|
| Diet, Reducing | 2 | 2018 | 470 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2013 | 6451 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1406 | 0.060 |
Why?
|
| Metformin | 1 | 2009 | 800 | 0.060 |
Why?
|
| Uridine | 1 | 2022 | 147 | 0.060 |
Why?
|
| Streptozocin | 1 | 2022 | 207 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 1817 | 0.060 |
Why?
|
| United States | 3 | 2016 | 67165 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2016 | 8992 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 50597 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 2716 | 0.050 |
Why?
|
| Anaerobic Threshold | 1 | 2020 | 54 | 0.050 |
Why?
|
| Health Status | 1 | 2014 | 4015 | 0.050 |
Why?
|
| Middle East | 1 | 2019 | 197 | 0.050 |
Why?
|
| United Nations | 1 | 2019 | 149 | 0.040 |
Why?
|
| Risk | 1 | 2011 | 9641 | 0.040 |
Why?
|
| Pregnancy | 1 | 2019 | 26832 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2012 | 10507 | 0.040 |
Why?
|
| Arabs | 1 | 2019 | 130 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 469 | 0.040 |
Why?
|
| Weight Loss | 1 | 2009 | 2450 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 84718 | 0.040 |
Why?
|
| Prevalence | 1 | 2014 | 14712 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4424 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 23950 | 0.040 |
Why?
|
| Seeds | 1 | 2016 | 101 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2019 | 12366 | 0.040 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2016 | 229 | 0.030 |
Why?
|
| Sex Factors | 2 | 2020 | 10566 | 0.030 |
Why?
|
| Metabolomics | 1 | 2022 | 1357 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 1794 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2020 | 3879 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 23020 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 8024 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 1513 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 2014 | 340 | 0.030 |
Why?
|
| Graves Disease | 1 | 2014 | 249 | 0.030 |
Why?
|
| Asian Americans | 1 | 2017 | 699 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1110 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2018 | 869 | 0.030 |
Why?
|
| Motor Activity | 1 | 2022 | 2749 | 0.030 |
Why?
|
| Algorithms | 1 | 2012 | 13647 | 0.030 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2014 | 328 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 2000 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 1504 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4261 | 0.020 |
Why?
|
| Lung | 1 | 2008 | 9706 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39038 | 0.020 |
Why?
|
| Body Composition | 1 | 2018 | 2393 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3417 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 23284 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9754 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 80876 | 0.020 |
Why?
|
| Rats | 1 | 2020 | 25094 | 0.020 |
Why?
|
| Homeostasis | 1 | 2014 | 3334 | 0.010 |
Why?
|
| Animals | 3 | 2022 | 170486 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 2996 | 0.010 |
Why?
|
| African Americans | 1 | 2017 | 5118 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 7989 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16306 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12292 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 13536 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 61932 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 71483 | 0.010 |
Why?
|
Concepts
(161)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_